Prelude Therapeutics (PRLD)

• Market cap: $55M
• 1 day: 1.44%
• 5 days: -18.84%
• 1 month: 10.27%
• 3 months: 29.01%
• 6 months: 8.73%
• Year to date: -22.09%
• 1 year: -75.22%
• 5 years: -96.28%
• 10 years: -96.28%
• Sector: Healthcare
• Industry: Biotechnology

About: Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Employees: 131

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

6% less funds holding

Funds holding: 62 [Q4 2024] → 58 (-4) [Q1 2025]

21.0% less ownership

Funds ownership: 76.25% [Q4 2024] → 55.26% (-21.0%) [Q1 2025]

25% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 24

34% less capital invested

Capital invested by funds: $41M [Q4 2024] → $26.9M (-$14.1M) [Q1 2025]

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4 311% upside
• Avg. target: $4.50 362% upside
• High target: $5 413% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Robert Burns	413% upside $5	Buy Reiterated	5 May 2025
JMP Securities Reni Benjamin	311% upside $4	Market Outperform Reiterated	29 Apr 2025